Category - Developments

Developments

Hepion Pharma moving into Phase 2b NASH trial after additional positive Phase 2a data

Hepion Pharmaceuticals (NASDAQ:HEPA) is initiating a Phase 2b clinical trial after releasing additional positive efficacy data from its Phase 2a AMBITION trial with CRV431 for the treatment of non-alcoholic...

September 13, 2021

Developments

IntelGenx partner launches RIZAPORT for acute migraine in Spain

IntelGenx’s (TSXV:IGX; OTCQB:IGXT) commercialization partner in the EU, Exeltis Healthcare, launched RIZAPORT, a unique treatment of acute migraine, in Spain. RIZAPORT is based on IntelGenx’s...

September 8, 2021

Developments

111, Inc. in $10-million share repurchase program

The board of Shanghai-based 111, Inc. (NASDAQ:YI) authorized a share repurchase program of up to $10-million of the company’s Class A ordinary shares in the form of American depositary shares in the next 12 months. The...

September 7, 2021

Developments

IntelGenx ships CBD filmstrips to Heritage Cannabis to support market launch

IntelGenx (TSXV:IGX; OTCQB:IGXT) completed an initial shipment of CBD Filmstrips in support of Heritage Cannabis Holdings’ (CSE:CANN) Canadian market launch of its “CB4 Control” branded product. The CBD Filmstrips were...

August 31, 2021

Developments

Sigyn Therapeutics featured on NPR’s Tech Nation

Jim Joyce, CEO of Sigyn Therapeutics (OTC Markets:SIGY) was interviewed by National Public Radio’s Tech Nation about the treatment of life-threatening inflammatory conditions precipitated by cytokine storm syndrome. In...

August 30, 2021

Developments

111 Inc. Q2 net revenue jumps 86.5%

Shanghai-based 111 Inc. reported net revenue rose 86.5% for the second quarter to $468.4-million (RMB3.0-billion). Mr. Junling Liu, co-founder, chairman, and CEO of 111, said the second quarter represented another...

August 27, 2021

Developments

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Raymond James gave winning marks to Profound Medical‘s (NASDAQ:PROF; TSX:PRN) TULSA-PRO device, compared with the Focal One HIFU device from France’s EDAP TMS SA (NASDAQ:EDAP), in a head-to-head comparison study...

August 26, 2021

Developments

FSD Pharma to acquire Lucid Psycheceuticals

FSD Pharma (NASDAQ:HUGE; CSE:HUGE; FRA:0K9A) agreed to acquire all the shares of closely-held, Lucid Psycheceuticals, for approximately $9-million in FSD Pharma stock. “Lucid has successfully developed a strong...

August 25, 2021

Developments

FDA clears Vifor, Cara pruritus injection associated with CKD

The FDA approved an NDA from Vifor Pharma and Cara Therapeutics (NASDAQ:CARA) for their KORSUVA injection for the treatment of moderate-to-severe pruritus (itch) associated with chronic kidney disease in adults...

August 24, 2021

Developments

Pfizer to acquire Trillium Therapeutics to expand immuno-oncology therapies

Pfizer (NYSE:PFE) entered into a definitive agreement to acquire Trillium Therapeutics (NASDAQ, TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. ...

August 23, 2021

Category - Developments

Hepion Pharma moving into Phase 2b NASH trial after additional positive Phase 2a data

IntelGenx partner launches RIZAPORT for acute migraine in Spain

111, Inc. in $10-million share repurchase program

IntelGenx ships CBD filmstrips to Heritage Cannabis to support market launch

Sigyn Therapeutics featured on NPR’s Tech Nation

111 Inc. Q2 net revenue jumps 86.5%

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

FSD Pharma to acquire Lucid Psycheceuticals

FDA clears Vifor, Cara pruritus injection associated with CKD

Pfizer to acquire Trillium Therapeutics to expand immuno-oncology therapies

General

More